Literature DB >> 28647219

Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections.

Yee-Huang Ku1, Khee-Siang Chan2, Chun-Chieh Yang2, Che-Kim Tan2, Yin-Ching Chuang1, Wen-Liang Yu3.   

Abstract

BACKGROUND/
PURPOSE: Aspergillus-associated infection might comprise up to 23-29% of severe influenza patients from the community throughout stay in an intensive care unit (ICU). In Taiwan, cases of severe influenza with aspergillosis are increasingly reported. Therefore, we describe the relative risk of mortality among severe influenza patients with aspergillosis and other coinfections compared to severe influenza patients without Aspergillus coinfections.
METHODS: We retrospectively reviewed 124 adult patients with severe influenza in a tertiary medical center in southern Taiwan from January 2015 through March 2016. The definition of probable aspergillosis required abnormal radiological findings and positive Aspergillus galactomannan (GM) antigen and/or Aspergillus isolation.
RESULTS: Probable aspergillosis (detected throughout the whole course) and other coinfections (only community-acquired) were diagnosed in 21 (17%) and 38 (31%) of all patients respectively. Klebsiella pneumoniae (36.8%), Pseudomonas aeruginosa (31.6%) and Staphylococcus aureus (31.6%) were the most frequent isolates of other coinfections. In-ICU mortality of Aspergillus group (66.7%) was significantly higher than other coinfections (23.7%, p = 0.001) or control group without coinfections (15.4%, p < 0.001), with significant odds ratios after adjusting for important variables. The factor of GM index ≥0.6 had a 19.82 (95% CI, 4.91 to 80.07, p < 0.0001) odds of expiring in an ICU among the Aspergillus group.
CONCLUSION: Dual Aspergillus and influenza infection is emerging in southern Taiwan. Meanwhile, community-acquired P. aeruginosa should be listed in the common copathogens with severe influenza. The 67% mortality linked to aspergillosis highlights the need for physicians to focus attention on patients with GM ≥ 0.6.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Aspergillosis; Coinfection; Galactomannan; Influenza; Mortality

Mesh:

Year:  2017        PMID: 28647219     DOI: 10.1016/j.jfma.2017.06.002

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  24 in total

1.  Influenza Suppresses Neutrophil Recruitment to the Lung and Exacerbates Secondary Invasive Pulmonary Aspergillosis.

Authors:  Joshua M Tobin; Kara L Nickolich; Krishnaveni Ramanan; Matthew J Pilewski; Kristina D Lamens; John F Alcorn; Keven M Robinson
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

2.  Diagnostic value of galactomannan test in non-immunocompromised critically ill patients with influenza-associated aspergillosis: data from three consecutive influenza seasons.

Authors:  Linna Huang; Yingfang Zhang; Lin Hua; Qingyuan Zhan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-10       Impact factor: 3.267

Review 3.  Mechanistic Basis of Super-Infection: Influenza-Associated Invasive Pulmonary Aspergillosis.

Authors:  Keven Mara Robinson
Journal:  J Fungi (Basel)       Date:  2022-04-22

4.  Tendency in Pulmonary Aspergillosis Investigation during the COVID-19 Era: What Is Changing?

Authors:  Giuseppina Caggiano; Francesca Apollonio; Mila Consiglio; Valentina Gasparre; Paolo Trerotoli; Giusy Diella; Marco Lopuzzo; Francesco Triggiano; Stefania Stolfa; Adriana Mosca; Maria Teresa Montagna
Journal:  Int J Environ Res Public Health       Date:  2022-06-09       Impact factor: 4.614

Review 5.  Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature.

Authors:  Melisa M Shah; Eric I Hsiao; Carl M Kirsch; Amit Gohil; Supriya Narasimhan; David A Stevens
Journal:  Diagn Microbiol Infect Dis       Date:  2018-02-02       Impact factor: 2.803

6.  Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.

Authors:  Paul E Verweij; Bart J A Rijnders; Roger J M Brüggemann; Elie Azoulay; Matteo Bassetti; Stijn Blot; Thierry Calandra; Cornelius J Clancy; Oliver A Cornely; Tom Chiller; Pieter Depuydt; Daniele Roberto Giacobbe; Nico A F Janssen; Bart-Jan Kullberg; Katrien Lagrou; Cornelia Lass-Flörl; Russell E Lewis; Peter Wei-Lun Liu; Olivier Lortholary; Johan Maertens; Ignacio Martin-Loeches; M Hong Nguyen; Thomas F Patterson; Thomas R Rogers; Jeroen A Schouten; Isabel Spriet; Lore Vanderbeke; Joost Wauters; Frank L van de Veerdonk
Journal:  Intensive Care Med       Date:  2020-06-22       Impact factor: 17.440

7.  Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study.

Authors:  Frederike Waldeck; Filippo Boroli; Noémie Suh; Pedro David Wendel Garcia; Domenica Flury; Julia Notter; Anne Iten; Laurent Kaiser; Jacques Schrenzel; Katia Boggian; Marco Maggiorini; Jérôme Pugin; Gian-Reto Kleger; Werner Christian Albrich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-06-03       Impact factor: 3.267

8.  Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.

Authors:  Lore Vanderbeke; Nico A F Janssen; Roger J M Brüggemann; Joost Wauters; Dennis C J J Bergmans; Marc Bourgeois; Jochem B Buil; Yves Debaveye; Pieter Depuydt; Simon Feys; Greet Hermans; Oscar Hoiting; Ben van der Hoven; Cato Jacobs; Katrien Lagrou; Virginie Lemiale; Piet Lormans; Johan Maertens; Philippe Meersseman; Bruno Mégarbane; Saad Nseir; Jos A H van Oers; Marijke Reynders; Bart J A Rijnders; Jeroen A Schouten; Isabel Spriet; Karin Thevissen; Arnaud W Thille; Ruth Van Daele; Frank L van de Veerdonk; Paul E Verweij; Alexander Wilmer
Journal:  Intensive Care Med       Date:  2021-05-29       Impact factor: 17.440

9.  Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19.

Authors:  George R Thompson Iii; Oliver A Cornely; Peter G Pappas; Thomas F Patterson; Martin Hoenigl; Jeffrey D Jenks; Cornelius J Clancy; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

10.  Analysis of the clinical characteristics of 77 COVID-19 deaths.

Authors:  Kaige Wang; Zhixin Qiu; Jiasheng Liu; Tao Fan; Chunrong Liu; Panwen Tian; Ye Wang; Zhong Ni; Shumin Zhang; Jianfei Luo; Dan Liu; Weimin Li
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.